MediaCenter Panda Security

Betatester 2016 competition winners

Posted: 17 Aug 2015 02:56 AM PDT

contestet

We can finally announce the winners of the 2016 Beta competition!

The Betatester of the year, and winner of €600, is:

Jayakrishnan P, from India

Also, the 9 winners of €200 are:

Anil Kumar E.S, from India
Saravana Kumar S., from India
Andreas Ntonas, from Greece
S/o Ramakrishnan, from India
HUANG JIN KAI, from Taiwan
Lauri Säde, from Estonia
Manuel Gredilla, from Spain
Alex Molina, from Spain
Juan Pablo Sarria Aguilera, from Spain

Thanks to all those who participated for your comments and suggestions – your opinions are always important to us!

The post Betatester 2016 competition winners appeared first on MediaCenter Panda Security.

Comments

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition. In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates. So, why is this approval so important? First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com . Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead. CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday. It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly? The answer isn't clear yet. We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct. But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side

DBTECH

Search This Blog